Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.

ABSTRACT:

Importance

Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease. Pharmacological treatment options, including antipsychotics are not satisfactory.

Objective

The primary objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease. Key secondary objectives examined effects of citalopram on function, caregiver distress, safety, cognitive safety, and tolerability.

Design, setting, and participants

The Citalopram for Agitation in Alzheimer Disease Study (CitAD) was a randomized, placebo-controlled, double-blind, parallel group trial that enrolled 186 patients with probable Alzheimer disease and clinically significant agitation from 8 academic centers in the United States and

SUBMITTER: Porsteinsson AP 

PROVIDER: S-EPMC4086818 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature